

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

ANNOUNCEMENT POSITIVE PROFIT ALERT

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby informs the shareholders and potential investors of the Company that, based on the currently available unaudited management accounts of the Group for the six months ended 30 June 2024 (the “**Interim Period 2024**”) and the preliminary assessment by the Company’s management, the Group is expected to record a significant increase in an unaudited consolidated net profit of the Group of not less than RMB1,050 million for the Interim Period 2024 as compared to an unaudited consolidated net profit of the Group of approximately RMB11.6 million for the six months ended 30 June 2023.

The expected significant increase in net profit of the Group for the Interim Period 2024 are primarily attributed to (i) a significant profit recognised from redemption of the senior notes of the Company originally due in 2026 with discount; and (ii) a decrease in finance costs upon redemption of the related senior notes. For details of the relevant redemption of the senior notes, please refer to the Company’s announcements dated 3 January 2023, 31 July 2023, 7 December 2023, 24 January 2024, 20 February 2024, 1 March 2024, 11 March 2024 and 14 March 2024.

The Group is still in the process of finalizing its unaudited consolidated results for the Interim Period 2024. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited management accounts of the Group for the Interim Period 2024 and the information currently available to the Board, which may be subject to further adjustments after further internal review by the Board. Details of the unaudited financial performance of the Group will be contained in the interim results announcement of the Group for the Interim Period 2024, which is expected to be published on 29 August 2024.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Yestar Healthcare Holdings Company Limited
Liao Changxiang
Executive Director and Chief Executive Officer

16 August 2024

As at the date of this announcement, the executive Directors are Ms. Liao Changxiang and Ms. Wang Hong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Koeswondo Michael David.